Publication

Real-World eligibility for dapagliflozin in unselected heart failure patients: Data from the CORDIS-HF registry

This study aimed to investigate which proportion of patients with Heart Failure would be eligible for DAPA treatment in a real-world clinical practice.

Download Publication
Talk to an Expert
Data driving outcomes
For who
Technology
US log in
EU log in
Talk to an expert
Knowledge Center
Real-World eligibility for dapagliflozin in unselected heart failure patients: Data from the CORDIS-HF registry
Testimonial: University Hospital using LynxCare technology for Oncology research
Testimonial: Collaboration between a reference center in Cardiology and a top 5 pharmaceutical company facilitated through LynxCare
Contact
Stay in the know. Subscribe to our newsletter.
All rights reserved. Lynxcare Inc. | 1177 Avenue of the Americas, 7th floor, New York, USA

Download the research abstract

This study aimed to investigate which proportion of patients with Heart Failure would be eligible for DAPA treatment in a real-world clinical practice.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.